Medarex ( former NASDAQ symbol: MEDX ) is an American biotechnology company owned by Bristol Myers Squibb and based in Princeton, New Jersey. The company has manufacturing facilities in Bloomsbury and Annandale, New Jersey, and research facilities in Milpitas and Sunnyvale, California. Medarex specializes in therapeutic products based on monoclonal antibodies. In 2005 the Biotechnology Industry Organization (BIO) and the Long Island Life Sciences Initiative honored Medarex with a James D. Watson Helix Award.
Ipilimumab (also known as MDX-010 or MDX-101) is a human monoclonal antibody being developed by Medarex in conjunction with Bristol-Myers Squibb. It is intended to be used as a drug to activate the immune system. Ipilimumab has been undergoing clinical trials for the treatment of melanoma.
Acquisition by Bristol-Myers Squibb 
On July 22, 2009, biopharmaceutical drug manufacturer, Bristol-Myers Squibb, offered to acquire Medarex for $16 per share. By August 31, 2009 Bristol Meyers has acquired more than 90% of the outstanding common stock of Medarex and announced they will be filing for a short-form merger.
- medarex.com Corporate website
|This biotechnology article is a stub. You can help Wikipedia by expanding it.|
|This United States corporation or company article is a stub. You can help Wikipedia by expanding it.|